Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

M-Health Administered Sleep Treatment to Enhance Recovery in Bariatric Populations (MASTER) (MASTER)

15. marts 2021 opdateret af: Genna Popovich Hymowitz, Stony Brook University
This study is a longitudinal clinical trial designed to assess the feasibility of sleep intervention (Cognitive Behavioral Therapy for Insomnia (CBT-I)) in individuals with insomnia following bariatric surgery.

Studieoversigt

Status

Rekruttering

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 64 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18-64
  • Fluency with English
  • Willingness to maintain an active telehealth platform account
  • Daily access to wireless internet connection or sufficient cell phone service for telemedicine
  • Undergone bariatric surgery (Roux-en-Y or vertical sleeve gastrectomy) within past 1-3 years
  • Must have experienced <50% excess weight loss following surgery Clinically significant insomnia (i.e., ISI score >11)

Exclusion Criteria:

  • Patient underwent revision of initial weight loss procedure
  • PHQ-9 Depression score > 15
  • GAD-7 Anxiety score > 15
  • Current alcohol or substance abuse
  • Current narcotic use
  • Unstable major psychiatric condition
  • Restless leg syndrome
  • Sleep apnea with non-adherence to CPAP intervention (i.e., use of CPAP <4 nights/week)
  • Other problems at investigator discretion
  • Vulnerable populations (e.g., adults unable to consent, ages <18, pregnant women, and prisoners).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cognitive Behavioral Therapy for Insomnia
CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Andre navne:
  • CBT-I

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recruitment Rate
Tidsramme: Follow Up (week 15)
Number of participants screened into the study per month will help measure feasibility.
Follow Up (week 15)
Completion of Study Measures
Tidsramme: Follow Up (week 15)
The average percentage of study measures (self-report questionnaires, daily diaries and CBT-I sessions) that are completed across participants will help determine feasibility.
Follow Up (week 15)
ActiGraph Use
Tidsramme: Follow Up (week 15)
The average percentage of days spent wearing the medical-grade Fitbit-like-device that collects sleep and physical activity data to help assess feasibility.
Follow Up (week 15)
Actigraph Compliance
Tidsramme: Follow Up (week 15)
The average percentage of hours of wear per day of the medical-grade Fitbit-like-device that collects sleep and physical activity data to help assess feasibility.
Follow Up (week 15)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment Acceptability
Tidsramme: Follow Up (week 15)
Treatment Acceptability Questionnaire will measure acceptability with patient-reported treatment satisfaction, and open-ended questions about satisfaction with both CBT-I and telemedicine (e.g., "What did you think about treating sleep as part of your Bariatric care?"; "How did you feel about getting treatment without being face-to-face?"; "What could we do to improve your treatment experience?").
Follow Up (week 15)
Change in sleep onset latency
Tidsramme: Follow-up (week 15)
Sleep parameters will be measured by the ActiGraph model wGT3X-BT, a wrist-accelerometer.
Follow-up (week 15)
Change in wake after sleep onset (WASO)
Tidsramme: Follow-up (week 15)
Sleep parameters will be measured by the ActiGraph model wGT3X-BT, a wrist-accelerometer.
Follow-up (week 15)
Change in total sleep time (TST)
Tidsramme: Follow-up (week 15)
Sleep parameters will be measured by the ActiGraph model wGT3X-BT, a wrist-accelerometer.
Follow-up (week 15)
Change in sleep efficiency
Tidsramme: Follow-up (week 15)
This will be measured by actigraph data and data from participant daily sleep logs.
Follow-up (week 15)
Change in Insomnia Severity
Tidsramme: Visit 1 (Week 3), Visit 5 (Week 11), Follow up (Week 15)
The Insomnia Severity Index will be used to assess insomnia symptoms. The total score ranges from 0 to 63, with higher scores indicating more severe insomnia symptoms.
Visit 1 (Week 3), Visit 5 (Week 11), Follow up (Week 15)
% Excess Weight Loss
Tidsramme: Baseline (week 1), Follow-up (week 15)
Measured weight data will be extracted from electronic medical records. The following formula will be used to calculate % excess weight loss. %EWL = [(Initial Weight) - (Post Intervention Weight)] / [(Initial Weight) - (Ideal Weight)]. Ideal weight will be extracted from the EMR.
Baseline (week 1), Follow-up (week 15)
Change in BMI
Tidsramme: Baseline (week 1), Follow-up (week 15)
BMI will be extracted from electronic medical records and the formula: ΔBMI = (Initial BMI) - (BMI at week 15) will be used to calculate change in BMI.
Baseline (week 1), Follow-up (week 15)
% Total Weight Loss
Tidsramme: Baseline (week 1), Follow-up (week 15)
Weight data will be extracted from the electronic medical record. %TWL will be calculated using the following formula: % TWL= [(Initial Weight) - (Post intervention Weight)] / [(Initial Weight)]× 100
Baseline (week 1), Follow-up (week 15)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Genna F Popovich Hymowitz, Ph.D., Stony Brook University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. januar 2021

Primær færdiggørelse (Forventet)

1. november 2021

Studieafslutning (Forventet)

1. februar 2022

Datoer for studieregistrering

Først indsendt

27. oktober 2020

Først indsendt, der opfyldte QC-kriterier

2. november 2020

Først opslået (Faktiske)

6. november 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. marts 2021

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. marts 2021

Sidst verificeret

1. marts 2021

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner